Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Toxicology ; 465: 153049, 2022 01 15.
Artículo en Inglés | MEDLINE | ID: mdl-34818560

RESUMEN

The adverse physiological conditions have been long known to impact protein synthesis, folding and functionality. Major physiological factors such as the effect of pH, temperature, salt and pressure are extensively studied for their impact on protein structure and homeostasis. However, in the current scenario, the environmental risk factors (pollutants) have gained impetus in research because of their increasing concentrations in the environment and strong epidemiologic link with protein aggregation disorders. Here, we review the physiological and environmental risk factors for their impact on protein conformational changes, misfolding, aggregation, and associated pathological conditions, especially environmental risk factors associated pathologies.


Asunto(s)
Contaminantes Ambientales/efectos adversos , Proteínas/metabolismo , Deficiencias en la Proteostasis/inducido químicamente , Animales , Exposición a Riesgos Ambientales/efectos adversos , Humanos , Agregado de Proteínas , Agregación Patológica de Proteínas , Pliegue de Proteína , Estructura Terciaria de Proteína , Proteínas/química , Proteostasis , Deficiencias en la Proteostasis/metabolismo , Deficiencias en la Proteostasis/patología , Medición de Riesgo , Factores de Riesgo , Estrés Fisiológico , Relación Estructura-Actividad
2.
Sci Rep ; 10(1): 10028, 2020 06 22.
Artículo en Inglés | MEDLINE | ID: mdl-32572058

RESUMEN

Nano-particulate air pollution threatens developing brains and is epidemiologically related to neurodegenerative diseases involving deposition of misfolded proteins. However, the mechanism underlying developmental neurotoxicity by nanoparticles remains unknown. Here, we report that maternal exposure to low doses of carbon black nanoparticle (CB-NP) induces endoplasmic reticulum (ER) stress associated with accumulation of misfolded proteins. Notably, offspring specifically showed high induction of ER stress in perivascular macrophages and reactive astrocytes only around brain blood vessels, along with accumulation of ß-sheet-rich proteins regarded as misfolded proteins. Our results suggest that maternal CB-NP exposure induced ER stress in PVMs and reactive astrocytes around blood vessels in the brain of offspring in mice. The induction of ER stress accompanied by the perivascular accumulation of misfolded proteins is likely to be associated with perivascular abnormalities and neurodegeneration, and development of neurodegenerative diseases related to particulate air pollution.


Asunto(s)
Vasos Sanguíneos/efectos de los fármacos , Encéfalo/efectos de los fármacos , Estrés del Retículo Endoplásmico/efectos de los fármacos , Nanopartículas/efectos adversos , Deficiencias en la Proteostasis/inducido químicamente , Hollín/efectos adversos , Animales , Encéfalo/crecimiento & desarrollo , Recuento de Células , Femenino , Técnica del Anticuerpo Fluorescente , Masculino , Ratones , Ratones Endogámicos ICR , Embarazo , Efectos Tardíos de la Exposición Prenatal/inducido químicamente , Pliegue de Proteína/efectos de los fármacos
3.
Neurotoxicology ; 64: 267-277, 2018 01.
Artículo en Inglés | MEDLINE | ID: mdl-28450057

RESUMEN

Many chronic neurodegenerative disorders share a common pathogenic mechanism involving the aggregation and deposition of misfolded proteins. Recently, it was shown that these aggregated proteins could be transferred from one cell to another via extracellular nanovesicles called exosomes. Initially thought to be a means of cellular waste removal, exosomes have since been discovered to actively participate in cell-to-cell communication. Importantly, various inflammatory and signaling molecules, as well as small RNAs are selectively packaged in these vesicles. Considering the important role of environmental manganese (Mn) in Parkinson's disease (PD)-like neurological disorders, we characterized the effect of Mn on exosome content and release using an MN9D dopaminergic cell model of PD, which was generated to stably express wild-type human α-synuclein (αSyn). Mn exposure (300µM MnCl2) for 24h induced the release of exosomes into the extracellular media prior to cytotoxicity, as determined by NanoSight particle analysis and electron microscopy. Strikingly, Western blot analysis revealed that Mn treatment in αSyn-expressing cells increases the protein Rab27a, which regulates the release of exosomes from cells. Moreover, next-generation sequencing showed more small RNAs in exosomes isolated from Mn-exposed cells than from control exosomes. Our miRNA profiling analysis led to the discovery of increased expression of certain miRNAs previously shown to regulate key biological pathways, including protein aggregation, autophagy, inflammation and hypoxia. Collectively, our results provide a glimpse of Mn's role in modulating extracellular miRNA content through exosomal release from dopaminergic neuronal cells and thus potentially contributing to progressive neurodegeneration. Further characterization of extracellular miRNAs and their targets will have major impacts on biomarker discovery and translational strategies for environmentally linked neurodegenerative diseases including PD.


Asunto(s)
Exosomas/metabolismo , Manganeso/toxicidad , MicroARNs/metabolismo , Enfermedad de Parkinson Secundaria/metabolismo , alfa-Sinucleína/metabolismo , Células Cultivadas , Neuronas Dopaminérgicas/efectos de los fármacos , Neuronas Dopaminérgicas/metabolismo , Humanos , Deficiencias en la Proteostasis/inducido químicamente
4.
Eur J Nutr ; 55(2): 741-747, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25851110

RESUMEN

PURPOSE: Resveratrol is a polyphenol present in red wine for which the capability of directly interfering with the hallmark of Alzheimer's disease (AD), i.e. toxic ß-amyloid protein (Aß) aggregation, has been shown recently. Since the stimulation of proteostasis could explain reduced Aß-aggregation, we searched for proteostasis targets of resveratrol. METHODS: The transgenic Caenorhabditis elegans strain CL2006, expressing Aß1-42 under control of a muscle-specific promoter and responding to Aß-toxicity with paralysis, was used as a model. Target identification was accomplished through specific knockdowns of proteostasis genes by RNA interference. Effects of resveratrol on protein aggregation were identified using ProteoStat(®) Detection Reagent, and activation of proteasomal degradation by resveratrol was finally proven using a specific fluorogenic peptide substrate. RESULTS: Resveratrol at a concentration of 100 µM caused a 40 % decrease in paralysis. UBL-5 involved in unfolded protein response (UPR) in mitochondria proved to be necessary for the prevention of Aß-toxicity by resveratrol. Also XBP-1, which represents an endoplasmic reticulum-resident factor involved in UPR, was identified to be necessary for the effects of resveratrol. Regarding protein degradation pathways, the inhibition of macroautophagy and chaperone-mediated autophagy prevented resveratrol from reducing paralysis as did the inhibition of proteasomal degradation. Finally, resveratrol reduced the amount of lysosomes, suggesting increased flux of proteins through the autophagy pathways and activated proteasomal degradation. CONCLUSIONS: Resveratrol reduces the Aß-induced toxicity in a C. elegans model of AD by targeting specific proteins involved in proteostasis and thereby reduces the amount of aggregated Aß.


Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Péptidos beta-Amiloides/efectos adversos , Parálisis/tratamiento farmacológico , Fragmentos de Péptidos/efectos adversos , Estilbenos/farmacología , Animales , Autofagia/efectos de los fármacos , Caenorhabditis elegans , Proteínas de Caenorhabditis elegans/genética , Proteínas de Caenorhabditis elegans/metabolismo , Proteínas Portadoras/genética , Proteínas Portadoras/metabolismo , Modelos Animales de Enfermedad , Estrés del Retículo Endoplásmico/efectos de los fármacos , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Parálisis/inducido químicamente , Complejo de la Endopetidasa Proteasomal/metabolismo , Deficiencias en la Proteostasis/inducido químicamente , Deficiencias en la Proteostasis/tratamiento farmacológico , Interferencia de ARN , Resveratrol , Ubiquitinas/genética , Ubiquitinas/metabolismo , Respuesta de Proteína Desplegada/efectos de los fármacos
5.
Biochemistry ; 54(24): 3831-8, 2015 Jun 23.
Artículo en Inglés | MEDLINE | ID: mdl-26021642

RESUMEN

Protein misfolding and aggregation, leading to amyloid fibril formation, are characteristic of many devastating and debilitating amyloid diseases. Accordingly, there is significant interest in the mechanisms underlying amyloid fibril formation and identification of possible intervention tools. Small molecule drug compounds approved for human use or for use in phase I-III clinical trials were investigated for their effects on amyloid formation by human apolipoprotein (apo) C-II. Several of these compounds modulated the rate of amyloid formation by apoC-II. Epigallocatechin gallate (EGCG), a green tea catechin, was an effective inhibitor of apoC-II fibril formation, and the antipsychotic drug, fluphenazine·HCl, was a potent activator. Both EGCG and fluphenazine·HCl exerted concentration-dependent effects on the rate of fibril formation, bound to apoC-II fibrils with high affinity, and competitively reduced thioflavin T binding. EGCG significantly altered the size distribution of fibrils, most likely by promoting the lateral association of fibrils and subsequent formation of large aggregates. Fluphenazine·HCl did not significantly alter the size distribution of fibrils, but it may induce the formation of a small population of rod-like fibrils that differ from the characteristic ribbon-like fibrils normally observed for apoC-II. The findings of this study emphasize the effects of small molecule drugs on the kinetics of amyloid fibril formation and their roles in determining fibril structure and aggregate size.


Asunto(s)
Amiloide/efectos de los fármacos , Antipsicóticos/farmacología , Apolipoproteína C-II/química , Catequina/análogos & derivados , Drogas en Investigación/farmacología , Flufenazina/farmacología , Fármacos Neuroprotectores/farmacología , Amiloide/química , Amiloide/metabolismo , Amiloide/ultraestructura , Antipsicóticos/efectos adversos , Apolipoproteína C-II/genética , Apolipoproteína C-II/metabolismo , Apolipoproteína C-II/ultraestructura , Benzotiazoles , Unión Competitiva , Catequina/farmacología , Catequina/uso terapéutico , Descubrimiento de Drogas , Drogas en Investigación/efectos adversos , Drogas en Investigación/uso terapéutico , Flufenazina/efectos adversos , Humanos , Cinética , Microscopía Electrónica de Transmisión , Fármacos Neuroprotectores/uso terapéutico , Tamaño de la Partícula , Agregado de Proteínas/efectos de los fármacos , Conformación Proteica/efectos de los fármacos , Deficiencias en la Proteostasis/inducido químicamente , Deficiencias en la Proteostasis/tratamiento farmacológico , Deficiencias en la Proteostasis/metabolismo , Deficiencias en la Proteostasis/patología , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Proteínas Recombinantes/ultraestructura , Bibliotecas de Moléculas Pequeñas , Tiazoles/antagonistas & inhibidores , Tiazoles/metabolismo , Ultracentrifugación
6.
Biochem J ; 457(3): 485-96, 2014 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-24200403

RESUMEN

EDEM1 [ER (endoplasmic reticulum)-degradation-enhancing α-mannosidase I-like protein 1] and EDEM2 are crucial regulators of ERAD (ER-associated degradation) that extracts non-native glycoproteins from the calnexin chaperone system. Ricin is a potent plant cytotoxin composed of an A-chain (RTA) connected by a disulfide bond to a cell-binding lectin B-chain (RTB). After endocytic uptake, the toxin is transported retrogradely to the ER, where the enzymatically active RTA is translocated to the cytosol in a similar manner as misfolded ER proteins. This transport is promoted by EDEM1. In the present study we report that EDEM2 is also involved in ricin retrotranslocation out of the ER. However, the role of EDEM1 and EDEM2 in ricin transport to the cytosol seems to differ. EDEM2 promotes ricin retrotranslocation irrespectively of ER translocon accessibility; moreover, co-immunoprecipitation and pull-down studies revealed that more ricin can interact with EDEM2 in comparison with EDEM1. On the other hand, interactions of both lectins with RTA are dependent on the structure of the RTA. Thus our data display a newly discovered role for EDEM2. Moreover, analysis of the involvement of EDEM1 and EDEM2 in ricin retrotranslocation to the cytosol may provide crucial information about general mechanisms of the recognition of ERAD substrates in the ER.


Asunto(s)
Sustancias para la Guerra Química/toxicidad , Citosol/metabolismo , Retículo Endoplásmico/metabolismo , Lectinas/metabolismo , Proteínas de la Membrana/metabolismo , Ricina/toxicidad , Sustitución de Aminoácidos , Animales , Supervivencia Celular/efectos de los fármacos , Sustancias para la Guerra Química/química , Glicoproteínas , Células HEK293 , Humanos , Riñón/efectos de los fármacos , Riñón/metabolismo , Riñón/patología , Lectinas/biosíntesis , Lectinas/genética , Proteínas de la Membrana/biosíntesis , Proteínas de la Membrana/genética , Ratones , Proteínas Mutantes/química , Proteínas Mutantes/toxicidad , Inhibidores de Proteasoma/farmacología , Estabilidad Proteica/efectos de los fármacos , Subunidades de Proteína/química , Subunidades de Proteína/toxicidad , Transporte de Proteínas/efectos de los fármacos , Desplegamiento Proteico/efectos de los fármacos , Deficiencias en la Proteostasis/inducido químicamente , Deficiencias en la Proteostasis/metabolismo , Deficiencias en la Proteostasis/patología , Proteínas Recombinantes de Fusión/biosíntesis , Proteínas Recombinantes de Fusión/metabolismo , Ricina/química , Ricina/genética , alfa-Manosidasa
7.
J Alzheimers Dis ; 33(2): 339-48, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-22936006

RESUMEN

Misfolded, N- and C-terminally truncated tau protein is the primary constituent of neurofibrillary tangles in brains of patients afflicted with Alzheimer's disease (AD). Intracellular accumulation of misfolded and truncated tau leads to generation of cytotoxic intermediates; transgenic expression of truncated tau leads to neurological deficits, neurofibrillary degeneration, and premature death of animals. Since no cure for AD or other tauopathies is available yet, we tested the possibility for prevention of pathogenic events elicited by tau, via inhibition of its intracellular accumulation. Using a cell model conditionally expressing truncated and misfolding-prone tau protein, we showed that pathogenic forms of tau are degraded via the proteasome. We have also observed that chymotrypsin-like activity of the proteasome was significantly suppressed (a decrease of ∼29.12% in comparison to control cells; p < 0.001) as a consequence of truncated tau expression. Interestingly, the activity of the proteasome was enhanced by geldanamycin, a natural inhibitor of Hsp90. This activation resulted in accelerated degradation of misfolded tau. We suggest that non-toxic inhibitors of Hsp90, especially those which can activate the proteasome, are good candidates for the development of molecules that efficiently counteract the damaging effects of pathologically misfolded proteins.


Asunto(s)
Benzoquinonas/toxicidad , Lactamas Macrocíclicas/toxicidad , Neuronas/patología , Complejo de la Endopetidasa Proteasomal/metabolismo , Deficiencias en la Proteostasis/metabolismo , Tauopatías/metabolismo , Proteínas tau/metabolismo , Animales , Células COS , Línea Celular Tumoral , Chlorocebus aethiops , Quimotripsina/metabolismo , Inhibidores de Cisteína Proteinasa/toxicidad , Proteínas HSP90 de Choque Térmico/antagonistas & inhibidores , Proteínas HSP90 de Choque Térmico/metabolismo , Humanos , Neuroblastoma , Ovillos Neurofibrilares/metabolismo , Ovillos Neurofibrilares/patología , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Pliegue de Proteína , Deficiencias en la Proteostasis/inducido químicamente , Deficiencias en la Proteostasis/patología , Tauopatías/inducido químicamente , Tauopatías/patología , Transgenes/genética , Proteínas tau/química , Proteínas tau/genética
8.
Toxicol Appl Pharmacol ; 264(2): 255-61, 2012 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-22959463

RESUMEN

Epidemiological studies of arsenic-exposed populations have provided evidence that arsenic exposure in humans is associated with immunosuppression. Previously, we have reported that arsenite-induced toxicity is associated with the induction of autophagy in human lymphoblastoid cell lines (LCL). Autophagy is a cellular process that functions in the degradation of damaged cellular components, including protein aggregates formed by misfolded or damaged proteins. Accumulation of misfolded or damaged proteins in the endoplasmic reticulum (ER) lumen causes ER stress and activates the unfolded protein response (UPR). In an effort to investigate the mechanism of autophagy induction by arsenite in the LCL model, we examined the potential contribution of ER stress and activation of the UPR. LCL exposed to sodium arsenite for 8-days induced expression of UPR-activated genes, including CHOP and GRP78, at the RNA and the protein level. Evidence for activation of the three arms of the UPR was observed. The arsenite-induced activation of the UPR was associated with an accumulation of protein aggregates containing p62 and LC3, proteins with established roles in the sequestration and autophagic clearance of protein aggregates. Taken together, these data provide evidence that arsenite-induced autophagy is associated with the generation of ER stress, activation of the UPR, and formation of protein aggregates that may be targeted to the lysosome for degradation.


Asunto(s)
Arsenitos/toxicidad , Autofagia/efectos de los fármacos , Sistema Linfático/citología , Proteoma/efectos de los fármacos , Deficiencias en la Proteostasis/inducido químicamente , Aminas , Análisis de Varianza , Western Blotting , Línea Celular , Proliferación Celular/efectos de los fármacos , Chaperón BiP del Retículo Endoplásmico , Estrés del Retículo Endoplásmico/efectos de los fármacos , Humanos , Indicadores y Reactivos , Sistema Linfático/efectos de los fármacos , Lisosomas/efectos de los fármacos , Lisosomas/metabolismo , Análisis por Micromatrices , Deficiencias en la Proteostasis/fisiopatología , ARN/biosíntesis , ARN/aislamiento & purificación , Respuesta de Proteína Desplegada/efectos de los fármacos
9.
Aging Cell ; 11(5): 856-66, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22734670

RESUMEN

Nutrient availability influences an organism's life history with profound effects on metabolism and lifespan. The association between a healthy lifespan and metabolism is incompletely understood, but a central factor is glucose metabolism. Although glucose is an important cellular energy source, glucose restriction is associated with extended lifespan in simple animals and a reduced incidence of age-dependent pathologies in humans. We report here that glucose enrichment delays mutant polyglutamine, TDP-43, FUS, and amyloid-ß toxicity in Caenorhabditis elegans models of neurodegeneration by reducing protein misfolding. Dysregulated metabolism is common to neurodegeneration and we show that glucose enrichment is broadly protective against proteotoxicity.


Asunto(s)
Proteínas de Caenorhabditis elegans/metabolismo , Caenorhabditis elegans/metabolismo , Glucosa/administración & dosificación , Enfermedades Neurodegenerativas/metabolismo , Deficiencias en la Proteostasis/metabolismo , Factores de Edad , Animales , Caenorhabditis elegans/efectos de los fármacos , Caenorhabditis elegans/genética , Restricción Calórica , Modelos Animales de Enfermedad , Glucosa/metabolismo , Longevidad , Enfermedades Neurodegenerativas/inducido químicamente , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Pliegue de Proteína , Proteolisis , Deficiencias en la Proteostasis/inducido químicamente
10.
Neurotoxicology ; 33(3): 545-57, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22370090

RESUMEN

Chaperones in the endoplasmic reticulum play vital roles in the folding, assembly, and post-translational modification of secretory proteins and also recycle, refold, or initiate degradation of misfolded proteins. Chaperone deficiencies in either amount or function are implicated in the etiology or pathogenesis of Alzheimer's disease and other protein folding disorders of the central nervous system. In this review, we discuss evidence that chaperones become pathologic through deleterious interactions with metals and then promote protein folding disorders. The "master regulator" chaperone GRP78 in the endoplasmic reticulum is a compelling subject for investigation in this context because it is located at the hub of signaling pathways in a complex chaperone network. It has therefore been studied by several laboratories in conjunction with exposure to toxic metals. The key points of this review are that metals are implicated in the etiology or pathogenesis of Alzheimer's disease and other protein folding disorders, metals induce the expression GRP78, often associated with oxidative stress, some metals bind to GRP78, and lead (Pb) impairs GRP78 function when it binds to GRP78. If certain metals do indeed cause or promote the aggregation of toxic proteins in the central nervous system, as the available evidence indicates, the identification of the mechanisms by which they act would provide valuable leads for the development of therapies to prevent or reverse toxic protein aggregation.


Asunto(s)
Retículo Endoplásmico/efectos de los fármacos , Metales/toxicidad , Chaperonas Moleculares/metabolismo , Neuronas/efectos de los fármacos , Síndromes de Neurotoxicidad/etiología , Deficiencias en la Proteostasis/inducido químicamente , Animales , Retículo Endoplásmico/metabolismo , Retículo Endoplásmico/patología , Chaperón BiP del Retículo Endoplásmico , Proteínas de Choque Térmico/metabolismo , Humanos , Neuronas/metabolismo , Neuronas/patología , Síndromes de Neurotoxicidad/metabolismo , Síndromes de Neurotoxicidad/patología , Pliegue de Proteína , Deficiencias en la Proteostasis/metabolismo , Deficiencias en la Proteostasis/patología , Medición de Riesgo , Factores de Riesgo
11.
Oncotarget ; 2(3): 209-21, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21444945

RESUMEN

Proteotoxic stress (PS) is generated in cells under a variety of conditions involving accumulation of misfolded proteins. To avoid the toxicity of unmitigated PS, cells activate the heat shock response (HSR). HSR involves upregulation of factors such as ubiquitin and the non-housekeeping chaperone Hsp70 which assist with metabolism of aberrant proteins. The PS-HSR axis is a potential anticancer treatment target since many tumor cells display constitutive PS and dependence on HSR due to their rapid rates of proliferation and translation. In fact, induction of PS via stimulation of protein misfolding (hyperthermia), inhibition of proteasomes (bortezomib) or inhibition of Hsp90 (geldanamycin) have all been considered or used for cancer treatment. We found that combination of bortezomib with an inducer of protein misfolding (hyperthermia or puromycin) resulted in enhanced PS. HSR was also induced, but could not mitigate the elevated PS and the cells died via largely p53-independent apoptosis. Thus, combination treatments were more cytotoxic in vitro than the component single treatments. Consistent with this, combination of non-toxic doses of puromycin with bortezomib significantly increased the antitumor activity of bortezomib in a mouse model of multiple myeloma. These results provide support for using combination treatments that disrupt the balance of PS and HSR to increase the therapeutic index of anticancer therapies.


Asunto(s)
Antineoplásicos/farmacología , Ácidos Borónicos/farmacología , Mieloma Múltiple/metabolismo , Mieloma Múltiple/terapia , Inhibidores de Proteasoma , Deficiencias en la Proteostasis/metabolismo , Pirazinas/farmacología , Animales , Antimetabolitos Antineoplásicos/administración & dosificación , Antimetabolitos Antineoplásicos/farmacología , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Ácidos Borónicos/administración & dosificación , Bortezomib , Línea Celular Tumoral , Terapia Combinada , Sinergismo Farmacológico , Células HCT116 , Proteínas HSP70 de Choque Térmico/biosíntesis , Proteínas HSP90 de Choque Térmico/biosíntesis , Células HeLa , Respuesta al Choque Térmico/efectos de los fármacos , Humanos , Hipertermia Inducida , Ratones , Ratones Endogámicos BALB C , Mieloma Múltiple/tratamiento farmacológico , Complejo de la Endopetidasa Proteasomal/metabolismo , Deficiencias en la Proteostasis/inducido químicamente , Puromicina/administración & dosificación , Puromicina/farmacología , Pirazinas/administración & dosificación
12.
Endocrinology ; 151(10): 4717-24, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20685871

RESUMEN

It is well known that interfaces, such as polar-nonpolar or liquid-air, play a key role in triggering protein aggregation in vitro, in particular the aggregation of peptides and proteins with the predisposition of misfolding and aggregation. Here we show that the interface present in the lungs predisposes the lungs to form aggregation of inhaled insulin. Insulin inhalers were introduced, and a large number of diabetic patients have used them. Although inhalers were safe and effective, decreases in pulmonary capacity have been reported in response to inhaled insulin. We hypothesize that the lung air-tissue interface provides a template for the aggregation of inhaled insulin. Our studies were designed to investigate the harmful potential that inhaled insulin has in pulmonary tissue in vivo, through an amyloid formation mechanism. Our data demonstrate that inhaled insulin rapidly forms amyloid in the lungs causing a significant reduction in pulmonary air flow. Our studies exemplify the importance that interfaces play in protein aggregation in vivo, illustrating the potential aggregation of inhaled proteins and the formation of amyloid deposits in the lungs. These insulin deposits resemble the amyloid structures implicated in protein misfolding disorders, such as Alzheimer's and Parkinson's diseases, and could as well be deleterious in nature.


Asunto(s)
Insulina/administración & dosificación , Insulina/metabolismo , Insulina/toxicidad , Enfermedades Pulmonares/inducido químicamente , Deficiencias en la Proteostasis/inducido químicamente , Administración por Inhalación , Amiloide/metabolismo , Amiloide/toxicidad , Animales , Glucemia/efectos de los fármacos , Glucemia/metabolismo , Caspasa 9/metabolismo , Línea Celular , Precipitación Química , Complicaciones de la Diabetes/inducido químicamente , Complicaciones de la Diabetes/metabolismo , Evaluación Preclínica de Medicamentos , Activación Enzimática/efectos de los fármacos , Humanos , Enfermedades Pulmonares/metabolismo , Ratones , Ratones Endogámicos C57BL , Multimerización de Proteína/efectos de los fármacos , Multimerización de Proteína/fisiología , Deficiencias en la Proteostasis/metabolismo , Proteínas Recombinantes/metabolismo , Proteínas Recombinantes/toxicidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...